Goldenseal Hydrastis canadensis
Also called: yellow root, goldenroot, yellow pucoon
Goldenseal, Hydrastis canadensis, is a plant with a bright yellow rhizome (underground stem) that is used in supplements. Wild goldenseal has been overharvested and is available only in limited amounts; it is also grown commercially.
- Category
- Botanical
- Part used
- Rhizome (underground stem)
- Strongest evidence
- C Limited
- Reviewed
- 2026-10-28
Class 3 Limited studies in people. No randomized controlled trial of goldenseal for a health outcome was found, and NCCIH states no rigorous studies have evaluated its effects on health conditions in people. Human studies are small drug-interaction studies, such as an open-label crossover study in adults with type 2 diabetes. [4]
Fact-checked 2026-10-28 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CHeart and blood vessels1 topic
DSeveral areas, whole body or blood1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Health conditions in general | D | NCCIH reports that no rigorous studies have evaluated goldenseal's effects on health conditions in people, and there is not enough evidence to judge any use. [1] |
| Blood sugar, cholesterol and weight (berberine studies) | C | Studied with berberine itself, not goldenseal; NCCIH notes little berberine may be absorbed from oral goldenseal, so those results may not apply. [1] |
Main constituents: Berberine [1]; (-)-β-Hydrastine (with berberine, a time-dependent CYP3A inhibitor in laboratory studies) [3]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Small studies used about 3 g per day for short periods without serious harm; safety of longer use is uncertain. [1]
- Interaction study regimens: a single 3-g dose, and 1 g three times daily for six days. [3]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingNCCIH: women who are pregnant or breastfeeding should not use goldenseal; goldenseal should not be given to infants.
3 statements in the profile.
Details and sources - Interactions with medicines3 listed
Midazolam and other CYP3A substrates; Metformin; Other medications
Details and sources - Cancer evaluations (IARC, NTP)2 found
Each names the exact material tested, which may differ from a supplement.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsStated
Health Canada (monograph dated November 29, 2024), adults 18 and older, oral: 0.6-3 grams of dried root and rhizome per day.
Details and sources
Interactions
| With | What happens |
|---|---|
| Midazolam and other CYP3A substrates | In a clinical study, oral midazolam AUC and Cmax rose about 40–60% after goldenseal (single 3-g dose or 1 g three times daily for 6 days), mainly through inhibition of intestinal CYP3A; (-)-β-hydrastine was implicated as the main contributor. [3] |
| Metformin | In an NCCIH-funded study, metformin levels dropped about 25% in healthy adults taking goldenseal extract. [1] |
| Metformin (type 2 diabetes) | In a 2025 crossover study in adults with type 2 diabetes, the overall interaction was not clinically meaningful (metformin AUC ratio 0.93), although AUC fell about 20% at low metformin doses (500–750 mg). [4] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- Some commercial products contained other herbs or ingredients not on the label, in addition to or instead of goldenseal. [1]
Regulatory status
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming goldenseal or Hydrastis canadensis was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P3]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- IARC: goldenseal root powder is classified in Group 2B (possibly carcinogenic to humans), IARC Monographs Volume 108 (2016). [P4]
- NTP TR-562 (2010), goldenseal root powder in feed for 2 years: clear evidence of carcinogenic activity in male and female F344/N rats (hepatocellular adenoma; in males also adenoma or carcinoma combined); some evidence in male B6C3F1 mice (hepatoblastoma and multiple hepatocellular adenoma); no evidence in female B6C3F1 mice. [P1]
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- Midazolam and other CYP3A substrates: In a clinical study, oral midazolam AUC and Cmax rose about 40-60% after goldenseal (single 3-g dose or 1 g three times daily for 6 days), mainly through inhibition of intestinal CYP3A; (-)-β-hydrastine was implicated as the main contributor. [P2]
- Metformin: In an NCCIH-funded study, metformin levels dropped about 25% in healthy adults taking goldenseal extract. [P5]
- Other medications: Health Canada's monograph directs taking goldenseal a few hours before or after other medications or health products. [P7]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- Untargeted LC-MS metabolomics of 35 commercial goldenseal products found several outliers confirmed as originating from a non-goldenseal species or a mixture of plant materials (Wallace et al., 2018). [P8]
- NCCIH: some commercial goldenseal products contained other herbs or ingredients not on the label, in addition to or instead of goldenseal. [P5]
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test or examination of each dietary-ingredient component — 21 CFR 111.75(a)(1)(i) requires at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, unless FDA grants an exemption petition under 111.75(a)(1)(ii). [P9]
- Chemical fingerprint (e.g., LC-MS profile) against authenticated goldenseal — Products originating from non-goldenseal species or plant mixtures were detected by untargeted LC-MS metabolomics (Wallace et al., 2018). [P8]
Supply and conservation
- IUCN Red List: Vulnerable (VU), via GBIF species API, retrieved 2026-10-29. [P10]
- CITES Appendix II (current listing effective 13/09/2007, annotation #8: underground parts, i.e. roots and rhizomes, whole, parts and powdered). [P11]
- Canada: Hydrastis canadensis is listed in Schedule 1 of the Species at Risk Act as a 'special concern' species; CITES export permits are required for whole plants and underground parts, while finished products such as extracts or capsules are not regulated. [P7]
- Wild goldenseal has been overharvested and is available only in limited amounts; it is also grown commercially, but cultivation is expensive. [P5]
Absorption in people
- After a single oral 2.7 g dose of goldenseal supplement containing 78 mg hydrastine in 11 healthy subjects, hydrastine Cmax was 225 ± 100 ng/ml, Tmax 1.5 ± 0.3 h and elimination half-life 4.8 ± 1.4 h; hydrastine underwent rapid and extensive phase I and phase II metabolism. [P12]
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- Health Canada (monograph dated November 29, 2024), adults 18 and older, oral: 0.6-3 grams of dried root and rhizome per day. [P7]
Pregnancy and breastfeeding
Sources for this profile
- National Toxicology Program. TR-562: Toxicology and Carcinogenesis Studies of Goldenseal Root Powder (Hydrastis canadensis) in F344/N Rats and B6C3F1 Mice (Feed Studies) (2010), abstract, 2010-08. ntp.niehs.nih.gov
- Nguyen JT, et al. An integrative approach to elucidate mechanisms underlying the pharmacokinetic goldenseal-midazolam interaction. J Pharmacol Exp Ther 2023;387(3):252-264 (PMID 37541764), 2023-12. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1-142 (last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
- NCCIH. Goldenseal (Last Updated: February 2025), 2025-02. nccih.nih.gov
- NCCIH. Berberine: what the science says (Last Updated: June 2023), 2023-06. nccih.nih.gov
- Health Canada, NNHPD. Monograph: Goldenseal - Hydrastis canadensis - Oral (date 2024-11-29), 2024-11-29. webprod.hc-sc.gc.ca
- Wallace ED, Oberlies NH, Cech NB, Kellogg JJ. Detection of adulteration in Hydrastis canadensis (goldenseal) dietary supplements via untargeted mass spectrometry-based metabolomics. Food Chem Toxicol 2018;120:439-447 (PMID 30031041), 2018-10. pubmed.ncbi.nlm.nih.gov
- eCFR. 21 CFR 111.75 What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
- GBIF species API: IUCN Red List category for Hydrastis canadensis L., 2026-10-29. api.gbif.org
- CITES Species+ (UNEP-WCMC). Hydrastis canadensis L.: CITES listings (API record retrieved 2026-10-29), 2026-10-29. speciesplus.net
- Gupta PK, et al. Hydrastine pharmacokinetics and metabolism after a single oral dose of goldenseal (Hydrastis canadensis) to humans. Drug Metab Dispos 2015;43(4):534-552 (PMID 25609220), 2015-04. pubmed.ncbi.nlm.nih.gov
Sources
- NCCIH. Goldenseal (Last Updated: February 2025), 2025-02. nccih.nih.gov
- NCCIH. Berberine: what the science says (Last Updated: June 2023), 2023-06. nccih.nih.gov
- Nguyen JT, et al. An integrative approach to elucidate mechanisms underlying the pharmacokinetic goldenseal-midazolam interaction. J Pharmacol Exp Ther 2023;387(3):252-264 (MEDLINE record), 2023-12. pesquisa.bvsalud.org
- Nguyen JT, et al. The pharmacokinetic interaction between metformin and the natural product goldenseal is metformin dose-dependent: a three-arm crossover study in adults with type 2 diabetes. Clin Transl Sci 2025;18(2):e70120 (PMID 39943692), 2025-02. pubmed.ncbi.nlm.nih.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.